NETSCOUT Reports Third Quarter Fiscal Year 2026 Financial Results Quarterly Results Exceed Top and Bottom-Line Expectations Company Raises Midpoint of Fiscal Year 2026 Top- and Bottom-line Outlook Ranges WESTFORD, Mass., February 5, 2026 – NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT), a leading provider of enterprise network observability, carrier service assurance, cybersecurity, and Distributed-Denial-of-Service (DDoS) protection solutions, today announced financial results for its third quarter ended December 3 ...

Exhibit 99.1 Intercontinental Exchange Reports Strong Full Year 2025 Results 20th consecutive year of record revenues · 2025 net revenues of $9.9 billion, +7% y/y Jeff Sprecher, ICE Chair & Chief Executive Of icer, said, "As we close out 2025, we are pleased to report our 20th consecutive year of record revenues and continued earnings per share growth, driven by the strength of our diversified 'all- weather' business model and the trust of our global customers. Across our exchanges, fixed income, and mortga ...

Exhibit 99.1 Highlights: Brad Nelson, Chief Executive Officer, commented, "We delivered results that exceeded our expectations, and we are building momentum as we head into boat-shows and the spring selling season. We're entering this window with right-sized dealer inventories and a team that continues to deliver on key initiatives – bringing leading-edge innovation to market, executing on operational and cost efficiencies, and maintaining disciplined production management." Nelson continued, "Within Master ...

Date: February 5, 2026 FOR IMMEDIATE RELEASE CONTACT: James Francis, VP - IR IR@maximus.com Maximus Reports Fiscal Year 2026 First Quarter Results Earnings outlook raised on resilient performance and strong pipeline supports future outlook (Tysons, Va. - February 5, 2026) - Maximus (NYSE: MMS), a leading provider of government services, reported financial results for the three months ended December 31, 2025. Highlights for the first quarter of fiscal year 2026 include: "Our first quarter results reflect res ...

Exhibit 99.1 News Release Contacts: Brooke Hart (Media) brooke.hart@hii-co.com (202) 264-7108 Segment operating income in 2025 was $717 million and segment operating margin was 5.7%, compared to $573 million and 5.0%, respectively, in 2024, the increase was driven by improved operating results across all business segments. 1 1 Diluted earnings per share for the full year was $15.39, compared to $13.96 in 2024. Christie Thomas (Investors) christie.thomas@hii-co.com (757) 380-2104 HII Reports Fourth Quarter a ...

FOR RELEASE ON: February 4, 2026 CONTACT: Robert Barry VP - Investor Relations 608-361-7530 robert.barry@regalrexnord.com REGAL REXNORD REPORTS STRONG FOURTH QUARTER 2025 FINANCIAL RESULTS, INCLUDING ORGANIC GROWTH ACCELERATION AND DATA CENTER ORDERS WORTH ~$735M MILWAUKEE, WI - Regal Rexnord Corporation (NYSE: RRX) 4Q Highlights Full Year 2025 Highlights Full Year 2026 Guidance • Introducing Guidance For 2026 GAAP Diluted Earnings Per Share In A Range Of $5.29 To $6.09 And For Adjusted Diluted Earnings Per ...

Revenue Performance - Total net revenue for Q4 2025 was $13.3 million, a decrease of 22.4% compared to $17.1 million in Q4 2024[6] - Total net revenue for the full year 2025 was $52.0 million, down 18.5% from $63.7 million in 2024[6] - Product revenue for Q4 2025 was $13,250 million, a decrease of 22.5% from $17,020 million in Q4 2024[37] - Total revenue for the twelve months ended December 31, 2025, was $51,951 million, down from $63,723 million in 2024, representing a decline of 18.5%[37] - Collaboration revenue for Q4 2025 was negligible at $0 million, down from $63 million in Q4 2024[37] Expenses - Research and development expenses for Q4 2025 were $50.8 million, up from $41.0 million in Q4 2024, reflecting increased clinical trial costs[7] - Overall R&D expenses for 2025 increased to $197.1 million from $127.6 million in 2024[7] - Selling and marketing expenses for Q4 2025 were $13.0 million, compared to $10.8 million in Q4 2024, primarily due to increased personnel costs[8] - General and administrative expenses for Q4 2025 were $17.7 million, up from $14.6 million in Q4 2024[9] - Total costs and operating expenses for Q4 2025 were $83,010 million, an increase of 22.6% compared to $67,659 million in Q4 2024[37] Net Loss - The net loss for Q4 2025 was $(64.7) million, or $(0.29) per share, compared to a net loss of $(48.4) million in Q4 2024[10] - The overall net loss for 2025 was $(265.9) million, or $(1.42) per share, compared to $(193.5) million in 2024[11] - The net loss for Q4 2025 was $64,654 million, compared to a net loss of $48,388 million in Q4 2024, reflecting a 33.7% increase in losses[37] - Net loss per share for Q4 2025 remained at $(0.29), consistent with Q4 2024[37] Cash and Assets - Cash balance as of December 31, 2025, was $737.1 million, expected to support operations into 2028[5] - Ocular Therapeutix, Inc. has approximately $737.1 million in cash and cash equivalents as of December 31, 2025, compared to $392.1 million in 2024, representing an increase of 88%[35] - Total current assets increased to $782.1 million in 2025 from $441.0 million in 2024, reflecting a growth of 77%[35] - The company's total assets reached $808.1 million in 2025, up from $457.9 million in 2024, indicating an increase of 76%[35] - Total stockholders' equity rose to $654.3 million in 2025 from $315.3 million in 2024, marking a growth of 107%[35] Clinical Trials and Product Development - The SOL-R Phase 3 trial completed randomization of 631 subjects, exceeding the target of 555 subjects[4] - The primary endpoint of the HELIOS-3 trial is a 2-step change in the ordinal diabetic retinopathy severity score (DRSS) at Week 52 from baseline[24] - Diabetic retinopathy (DR) affects over 103 million people globally, with fewer than 1% of the 6.4 million NPDR patients in the U.S. currently receiving treatment[27] - Ocular's investigational product AXPAXLI is currently in Phase 3 clinical trials for wet AMD and diabetic retinal disease, including NPDR[29] - The company is evaluating next steps for its investigational product OTX-TIC, which has completed a Phase 2 clinical trial for open-angle glaucoma[30] - The company anticipates submitting a new drug application for AXPAXLI based on positive data from the SOL-1 Phase 3 clinical trial for wet AMD[32] Accumulated Deficit - The company reported an accumulated deficit of $1.16 billion as of December 31, 2025, compared to $891.1 million in 2024[35]

Exhibit 99.1 SelectQuote, Inc. Reports Second Quarter of Fiscal Year 2026 Results Second Quarter of Fiscal Year 2026 – Consolidated Earnings Highlights Fiscal Year 2026 Guidance Ranges: Second Quarter Fiscal Year 2026 – Segment Highlights Senior Healthcare Services Life OVERLAND PARK, Kan., February 5, 2026--(BUSINESS WIRE)--SelectQuote, Inc. (NYSE: SLQT) reported consolidated revenue for the second quarter of fiscal year 2026 of $537.1 million compared to consolidated revenue for the second quarter of fisc ...

Exhibit 99.1 Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025 Financial results reflect disciplined execution and focus on delivering long-term growth (PRINCETON, N.J., February 5, 2026) – Bristol Myers Squibb (NYSE: BMY) today reports results for the fourth quarter and full-year of 2025. "We made significant progress in 2025, with real momentum in our Growth Portfolio and a strengthened balance sheet that provides the strategic flexibility to continue investing in growth ...

EXHIBIT 10.1 2. Amendments to Credit Agreement. The Credit Agreement (exclusive of all Schedules and all Exhibits thereto) is hereby amended such that, after giving effect to all such amendments, the Credit Agreement, as amended by this Agreement (exclusive of all Schedules and all Exhibits thereto), will read in its entirety as set forth in Exhibit A to this Agreement. 3. Representations. To induce Lender to enter into this Agreement, Loan Parties hereby represent to Lender as follows: (a) that each Loan P ...